Osman Saida, Lihana Raphael W, Kibaya Rukia M, Ishizaki Azumi, Bi Xiuqiong, Okoth Fredrick A, Ichimura Hiroshi, Lwembe Raphael M
Kenya Medical Research Institute, Nairobi, Kenya.
AIDS Res Hum Retroviruses. 2013 Jan;29(1):187-90. doi: 10.1089/AID.2012.0182. Epub 2012 Sep 18.
Drug use in Kenya dates back to the precolonial period but research among drug users in relation to human immunodeficiency virus (HIV)-associated risk and intervention strategies has been low. To evaluate HIV-1 diversity and drug resistance among injecting drug users (IDUs), a cross-sectional study involving 58 patients was carried out in Mombasa between February and March 2010. HIV-1 RNA was extracted from plasma and polymerase chain reaction using specific primers for HIV-1 reverse transcriptase was done. Population sequencing was done and subtypes were determined phylogenetically. The prevalent HIV-1 subtypes were A1 (52/58), D (5/58), and C (2/58). The prevalence of drug resistance was 13.8% (8/58) with detection of nucleoside reverse transcriptase inhibitor (NRTI) mutations, T215F (n=5), K219Q (n=3), M184V (n=1), and nonnucleoside RTI mutation, K103N (n=1). Antiretroviral therapy (ART) and its monitoring among infected Kenyan IDUs is feasible. Policymakers and service providers in HIV prevention initiatives should improve service delivery so as to measure ART coverage among IDUs to prevent further transmission of drug-resistant variants.
肯尼亚的吸毒现象可追溯到殖民前时期,但针对吸毒者中与人类免疫缺陷病毒(HIV)相关风险及干预策略的研究却很少。为评估注射吸毒者(IDU)中的HIV-1多样性和耐药性,2010年2月至3月间在蒙巴萨对58名患者开展了一项横断面研究。从血浆中提取HIV-1 RNA,并使用针对HIV-1逆转录酶的特异性引物进行聚合酶链反应。进行群体测序并通过系统发育分析确定亚型。流行的HIV-1亚型为A1(52/58)、D(5/58)和C(2/58)。耐药率为13.8%(8/58),检测到核苷类逆转录酶抑制剂(NRTI)突变,T215F(n = 5)、K219Q(n = 3)、M184V(n = 1),以及非核苷类RTI突变K103N(n = 1)。在受感染的肯尼亚注射吸毒者中开展抗逆转录病毒疗法(ART)及其监测是可行的。HIV预防倡议中的政策制定者和服务提供者应改善服务提供,以便衡量注射吸毒者中的ART覆盖率,防止耐药变异株的进一步传播。